2021
Candidate pharmacological treatments for substance use disorder and suicide identified by gene co‐expression network‐based drug repositioning
Cabrera‐Mendoza B, Martínez‐Magaña J, Monroy‐Jaramillo N, Genis‐Mendoza A, Fresno C, Fries GR, Walss‐Bass C, Armenta M, García‐Dolores F, Díaz‐Otañez C, Flores G, Vázquez‐Roque R, Nicolini H. Candidate pharmacological treatments for substance use disorder and suicide identified by gene co‐expression network‐based drug repositioning. American Journal Of Medical Genetics Part B Neuropsychiatric Genetics 2021, 186: 193-206. PMID: 33403748, DOI: 10.1002/ajmg.b.32830.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersBrain gene co-expression networksHub genesPotential pharmacological targetPost-mortem samplesPharmacological treatmentHigh riskCandidate treatmentPharmacological targetsSuicidal behaviorMAOA inhibitorsPrefrontal cortexNonsuicidesDGIdb databaseGene expression profilesPatientsCo-expression networkSuicideDisordersDrugsTreatmentDrug repositioningExpression profilesIndividuals
2016
Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations
Gonzalez-Covarrubias V, Martínez-Magaña JJ, Coronado-Sosa R, Villegas-Torres B, Genis-Mendoza AD, Canales-Herrerias P, Nicolini H, Soberón X. Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations. Pharmaceutical Research 2016, 33: 2644-2652. PMID: 27387170, DOI: 10.1007/s11095-016-1990-5.Peer-Reviewed Original ResearchConceptsGenetic variantsMajor continental groupsAllele frequency differencesSolute carrier gene familySignificant allele differencesDifferent Mexican populationsGene familyContinental groupsAllele differencesMexican MestizosAllele frequenciesRelevant targetsMore variationDifferent populationsDrug responseMexican populationPharmacogenetic variantsNative groupsVariantsPharmacogenetic targetsDifferent native groupsPopulationMicroarrayTransportersTarget